Tacrolimus (FK506) P-III Placebo-Controlled Double-Blind Study in Moderate to Severe Refractory Ulcerative Colitis Patients

Trial Profile

Tacrolimus (FK506) P-III Placebo-Controlled Double-Blind Study in Moderate to Severe Refractory Ulcerative Colitis Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2014

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 01 May 2012 Results published in Inflammatory Bowel Diseases.
    • 30 Sep 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top